Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Medtronic
Cerilliant
Julphar
QuintilesIMS
Mallinckrodt
Deloitte
Chinese Patent Office
Healthtrust
Novartis

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,026,281

« Back to Dashboard

Which drugs does patent 8,026,281 protect, and when does it expire?


Patent 8,026,281 protects ANTARA (MICRONIZED) and is included in one NDA.

Summary for Patent: 8,026,281

Title:Treating metabolic syndrome with fenofibrate
Abstract: A method of treating metabolic syndrome in a human diagnosed with metabolic syndrome by administering a therapeutically effective amount of fenofibrate over a treatment period. The results can include identifying a human as not having clinical metabolic syndrome after treatment, as compared to having metabolic syndrome before treatment.
Inventor(s): Doyle, Jr.; Ralph T. (Milford, NJ), Kling; Douglas F. (Parisippany, NJ), Rongen; Roelof M. L. (Caliton, NJ), Rotenberg; Keith S. (Danville, NJ)
Assignee: Lupin Atlantis Holdings, S.A. (Schaffhausen, CH)
Application Number:11/111,971
Patent Claim Types:
see list of patent claims
Use; Delivery; Formulation; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Lupin Atlantis
ANTARA (MICRONIZED)
fenofibrate
CAPSULE;ORAL021695-004Oct 18, 2013RXYesNo► Subscribe► Subscribe TREATING SEVERE HYPERTRIGLYCERIDEMIA
Lupin Atlantis
ANTARA (MICRONIZED)
fenofibrate
CAPSULE;ORAL021695-004Oct 18, 2013RXYesNo► Subscribe► Subscribe TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
Lupin Atlantis
ANTARA (MICRONIZED)
fenofibrate
CAPSULE;ORAL021695-005Oct 18, 2013RXYesNo► Subscribe► Subscribe TREATING SEVERE HYPERTRIGLYCERIDEMIA
Lupin Atlantis
ANTARA (MICRONIZED)
fenofibrate
CAPSULE;ORAL021695-005Oct 18, 2013RXYesNo► Subscribe► Subscribe TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
Colorcon
Cipla
McKesson
Merck
Cerilliant
US Department of Justice
QuintilesIMS
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot